东宝生物(300239) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥884,932,215.88, a decrease of 9.19% compared to ¥974,512,217.68 in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥85,982,726.28, down 28.28% from ¥119,885,372.42 in 2023[21]. - The basic earnings per share for 2024 was ¥0.1448, reflecting a decline of 28.32% from ¥0.2020 in 2023[21]. - The total assets at the end of 2024 were ¥2,624,919,556.21, a decrease of 4.27% from ¥2,742,011,238.13 at the end of 2023[21]. - The company reported a significant drop in cash flow from operating activities, with a net amount of ¥69,131,118.11 in 2024, down 65.33% from ¥199,394,288.50 in 2023[21]. - The company achieved operating revenue of 884.93 million yuan, a year-on-year decrease of 9.19%[59]. - Net profit attributable to shareholders was 85.98 million yuan, down 28.28% year-on-year[59]. Market and Industry Trends - The company is focusing on the health and nutrition market, emphasizing the development of high-value collagen products and expanding into new application areas such as new materials[30]. - The Chinese nutritional health food retail market exceeded $37 billion in 2023, with a compound annual growth rate of 7.0% over the past three years, indicating significant growth potential[32]. - The market for health products is projected to grow at a CAGR of 6.2%, reaching $44.2 billion by 2026[33]. - The demand for anti-aging products is increasing due to a growing awareness of health and wellness among consumers, leading to a rise in collagen-based skincare products[33]. - The aging population and rising disposable income are expected to stabilize the demand for the pharmaceutical and nutrition health market[34]. - Government policies are increasingly supportive of the health industry, emphasizing food and drug safety and promoting innovation in pharmaceuticals[35]. Research and Development - The company is actively involved in research and development to innovate new products and technologies in the biotechnology sector[14]. - The company has established a dual-driven R&D model focusing on independent innovation and collaborative research with various institutions[63]. - The company has a strong focus on research and development, with platforms like the first batch of key laboratories for gelatin in China, enhancing its innovation capabilities[53]. - The number of R&D personnel increased by 13.77% from 138 in 2023 to 157 in 2024, with R&D personnel now accounting for 11.34% of the total workforce[83]. - R&D expenditure for 2024 was approximately ¥38.76 million, representing 4.38% of operating revenue, a slight increase from 4.27% in 2023[83]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, and has held 9 meetings during the reporting period[151]. - The supervisory board has 3 members, including 1 employee representative, and has held 7 meetings in compliance with regulations[151]. - The company maintains good communication with investors through various channels, including annual performance briefings and investor interaction platforms[152]. - The company's governance practices align with legal and regulatory requirements, with no significant discrepancies noted[153]. - The company operates independently from its controlling shareholders, ensuring complete autonomy in business operations and management[154]. Strategic Initiatives - The company is focusing on developing high-quality, safe pharmaceutical and nutritional products to meet the evolving consumer demands[36]. - The company is expanding its product applications into medical fields, including the production of injectable gelatin products and materials for medical aesthetics[33]. - The company is actively pursuing international market opportunities, with steady growth in its hollow capsule export business[60]. - The company is enhancing its digital management systems to improve operational efficiency and cost control[58]. - The company plans to actively participate in domestic and international exhibitions to better understand global market dynamics and enhance customer cooperation[132]. Investment and Fundraising - The company reported a total fundraising amount of RMB 86,228.17 million, with a net amount of RMB 83,895.69 million, and a total usage of RMB 52,855.44 million, resulting in a usage ratio of 63.00%[106]. - The company has a remaining balance of RMB 40,749,521.18 in its fundraising account as of December 31, 2024, which is stored in a special fundraising account[109]. - The company has raised a total of 129,057,300.00 CNY for the "Collagen Peptide Nutritional Supplement Product Construction Project," which accounts for 32.53% of the net fundraising amount[116]. - The company plans to use part of the surplus fundraising for permanent working capital, pending approval from the board and shareholders[118]. Operational Efficiency - The company has implemented a digital transformation strategy to enhance supply chain management and cost control[66]. - The company is enhancing operational efficiency through digital system upgrades and aims to establish a comprehensive digital control system for dynamic optimization[136]. - The company has adjusted its fundraising strategy to include investment in financial products, generating a net income of CNY 1.0072 million from idle funds[125]. - The company is committed to ensuring timely and efficient decision-making to protect the rights of shareholders[186]. Employee Management - The total number of employees at the end of the reporting period was 1,385, with 518 in the parent company and 867 in major subsidiaries[197]. - The company has established a performance-oriented compensation and performance assessment policy to attract and retain talent[198]. - Training plans are tailored for different job categories, covering various aspects including corporate culture, management skills, and compliance with safety regulations[199]. - The educational background of employees showed 21 with master's degrees or above, 159 with bachelor's degrees, 548 with associate degrees, and 657 with other qualifications[197].